Pharmafile Logo

Sun Pharma

- PMLiVE

World Psoriasis Day: Almirall highlights impact of disease on patient well-being

Almost 77% of patients believe that psoriasis negatively affects their daily life and well-being

Psoriasis-Awareness-Day

Listening and hearing – how patients’ online behaviour can help us to improve wellbeing in psoriasis.

The following article was developed using information gathered through primary and secondary desk research, including a recent Social Listening project conducted by our team at Mednet.

Mednet Group

- PMLiVE

BMS launches campaign to highlight impact of psoriasis on patient well-being

An estimated 7.5 million people in the US are affected by some form of the condition

- PMLiVE

Almirall launches mini-series to highlight impact of psoriasis on patient well-being

Almost 77% of psoriasis patients report that the condition negatively affects their well-being

- PMLiVE

Eli Lilly to acquire Dice Therapeutics for approximately $2.4bn

The deal marks a significant expansion to Lilly's immunology pipeline

- PMLiVE

Amgen reports positive results for inflammatory disease drug Otezla in psoriatic arthritis

The inflammatory condition is estimated to affect nearly 38 million people worldwide

- PMLiVE

UCB’s Epicensus programme highlights need to address psoriasis care gap

The programme was published in Dermatology and Therapy

Infographic: Therapy Watch Psoriasis

Our PsO infographic offers an introduction to the real-world patient insights collected by our Therapy Watch PsO study.

Research Partnership

- PMLiVE

Happify Health and Almirall launch Claro to support psoriasis patients

The digital wellness app is now available to those with the condition living in the UK, Spain and Italy

- PMLiVE

Bristol Myers Squibb releases positive trial results for plaque psoriasis treatment

Plaque psoriasis is a chronic, systemic immune-mediated disease associated with multiple serious comorbidities

- PMLiVE

Amgen shares new Otezla data at American Academy of Dermatology congress 2022

Around 125 million people worldwide have psoriasis, including an estimated 14 million people in Europe

- PMLiVE

Janssen shares new clinical trial data on its psoriasis treatment Tremfya

The results were presented at the 2022 AAD Annual Meeting in March

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links